The estimated Net Worth of Christopher Simon, is at least $63.1 million dollars as of 6 June 2024. Mr. Simon owns over 104,516 units of Haemonetics stock worth over $31,434,389 and over the last 8 years he sold HAE stock worth over $22,237,461. In addition, he makes $9,398,200 as President, Chief Executive Officer et Director at Haemonetics.
Christopher has made over 23 trades of the Haemonetics stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 104,516 units of HAE stock worth $4,352,046 on 6 June 2024.
The largest trade he's ever made was exercising 196,746 units of Haemonetics stock on 29 June 2023 worth over $5,630,871. On average, Christopher trades about 14,507 units every 72 days since 2016. As of 6 June 2024 he still owns at least 433,877 units of Haemonetics stock.
You can see the complete history of Mr. Simon stock trades at the bottom of the page.
Christopher A. Simon serves as President, Chief Executive Officer, Director of the Company. He joined Haemonetics in May 2016 and our Board in September 2016. Mr. Simon previously served as a Senior Partner of McKinsey & Company where he led the Global Medical Products Practice. Mr. Simon was a consultant with McKinsey & Company beginning in 1993 and was the Lead Partner for McKinsey & Company’s strategy review with Haemonetics that launched in October 2015, where he gained invaluable insights into the Company’s business and markets. Together with management and the Board, he was the co-architect of the strategic plan that the Company is now implementing. Prior to his career at McKinsey & Company, Mr. Simon served in commercial roles with Baxter Healthcare Corporation and as a U.S. Army Infantry Officer in Korea with the 1st Ranger Battalion. He also currently serves on the Board of Directors of AdvaMed. Mr. Simon earned a Bachelor of Science in Economics from the Wharton School at the University of Pennsylvania and an M.B.A. from Harvard Business School.
As the President, Chief Executive Officer et Director of Haemonetics, the total compensation of Christopher Simon at Haemonetics is $9,398,200. There are no executives at Haemonetics getting paid more.
Christopher Simon is 56, he's been the President, Chief Executive Officer et Director of Haemonetics since 2016. There are 9 older and 4 younger executives at Haemonetics. The oldest executive at Haemonetics Corp. is Richard Meelia, 71, who is the Independent Chairman of the Board.
Over the last 21 years, insiders at Haemonetics have traded over $82,114,016 worth of Haemonetics stock and bought 334,931 units worth $14,646,550 . The most active insiders traders include Paul Black, Robert E Abernathy et Brad Nutter. On average, Haemonetics executives and independent directors trade stock every 13 days with the average trade being worth of $539,753. The most recent stock trade was executed by Stewart W Strong on 26 July 2024, trading 4,312 units of HAE stock currently worth $393,039.
haemonetics is the blood management company. our comprehensive portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood management continuum. collectively they help improve patient care, ensure patient safety, and reduce costs for blood and plasma collectors, hospitals, and patients around the world. our mission we believe that through proper blood management, our products and services can help our commercial plasma and blood center customers optimize their collection processes. we seek to help ensure a continual supply of high-quality plasma for biopharmaceuticals and blood components for therapeutic use at optimal costs, along with better blood management processes. working with our hospital customers, we seek to prevent a blood transfusion to the patient who doesn’t need one, or, if a transfusion is necessary, to ensure the transfusion of the right blood product, at the right time, in the right
Haemonetics executives and other stock owners filed with the SEC include: